14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CNAT ranks #12429 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Conatus Pharmaceuticals Inc. Stock Forecast NASDAQ:CNAT

$0.28 (2.13%)

Volume: 1M

Closed: Jan 19, 2022

Hollow Logo Score: -2.657

Conatus Pharmaceuticals Inc. Stock Forecast

$0.28 (2.13%)

Volume: 1M

Closed: Jan 19, 2022

Score Hollow Logo -2.657

Conatus Pharmaceuticals Inc. Company Profile

16745 West Bernardo Drive

San Diego CA 92127



Conatus Pharmaceuticals Inc.


Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease and raised transaminases, as well as for the treatment of patients with severe alcoholic hepatitis. The company was founded in 2005 and is headquartered in San Diego, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE